News | April 12, 2026
C4 Therapeutics and Roche launch bold push into next-generation cancer drug modality
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
